Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis

Area of Science:

• Pulmonology
• Pharmacology
• Infectious Diseases

Background:

• Macrolide antibiotics possess anti-inflammatory properties.
• Long-term macrolide administration is explored for reducing chronic obstructive pulmonary disease (COPD) exacerbations.

Observation:

• A systematic review and meta-analysis of six randomized controlled trials (1,485 patients) evaluated macrolide therapy for COPD.
• The primary outcome was the frequency of acute exacerbations during follow-up.

Findings:

• Macrolide therapy significantly reduced COPD exacerbations (RR = 0.62; p = 0.01).
• Erythromycin showed a potential benefit (p = 0.04), while azithromycin and clarithromycin did not reach statistical significance.
• Therapy duration exceeding six months demonstrated conclusive benefits (6-month: p = 0.009; 12-month: p = 0.03).
• Nonfatal adverse events were more frequent in macrolide groups (RR = 1.32; p = 0.01).

Implications:

• Long-term macrolide therapy, especially erythromycin for over six months, appears effective and safe for decreasing COPD exacerbations.
• Further research may clarify optimal macrolide selection and duration for COPD management.
• Clinicians should weigh the benefits of reduced exacerbations against potential increases in adverse events.